Navigation Links
InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
Date:2/7/2008

tion with InterMune's buyout of future royalties and milestones that would have been due under the previous license agreement with Marnac, Inc. and co-licensor KDL GmbH for the development and commercialization of pirfenidone.

As of December 31, 2007, InterMune had cash, cash equivalents and available-for-sale securities of approximately $235.3 million, compared with $214.5 million at December 31, 2006.

In October 2007, Targanta Therapeutics completed an initial public offering of its common stock, which resulted in the conversion of InterMune's interest in Targanta into approximately 3.0 million shares of Targanta common stock. As of December 31, 2007, InterMune recorded an unrealized gain of $5.7 million on 630,000 of those shares. The 630,000 shares met the criteria to be classified, as available-for-sale, marketable equity securities as they are estimated to qualify for sale within one year.

Dan Welch, President and Chief Executive Officer of InterMune, said, "The fourth quarter was a period of significant progress for InterMune. During the quarter, we significantly improved the potential economics of pirfenidone by eliminating all future royalties and milestones associated with a previous license and we acquired additional pirfenidone intellectual property that we believe will extend the exclusivity period for pirfenidone.

Mr. Welch continued, "We also recently completed the first two dose cohorts in the important Phase 1b study of ITMN-191, our first experience with the compound in patients chronically infected with the hepatitis C virus, and recently announced that we are planning to advance ITMN-191 to a 14-day triple combination study with Pegasus(R) and ribavirin. We look forward to the next 12 months as a pivotal period for InterMune, during which we expect to report the Phase 1b data on ITMN-191, execute a 14-day triple combination study of ITMN-191 and report the results from the Phase 3 CAPACITY program for pirfenidone." '/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... 2015 , ... It is now possible to separate two common disorders: post-traumatic ... tomography (SPECT) according to researchers from Amen Clinics, UCLA, Thomas Jefferson University, and ... is believed to be the largest brain imaging study ever, will be published on ...
(Date:7/1/2015)... N.C. and PARIS ... firm AgBiome, and Genective, key developer of biotech ... the discovery of new generations of insect control ... insect control to counter the realities of advancing ... Genective, aligning AgBiome,s unique insect control technology with ...
(Date:7/1/2015)... , July 1, 2015   Decision Resources ... cited advantages of Otezla are its oral administration, ... as reported by surveyed rheumatologists. Otezla was the ... the treatment of active psoriatic arthritis in ... standard of care includes conventional oral treatments including ...
(Date:7/1/2015)... ... ... The next-generation sequencing (NGS) clinical market is poised for huge growth as ... Research reveals in its new report that the market drivers of this vibrant industry ... for better diagnostics as part of a molecular diagnostics trend. , The global market ...
Breaking Biology Technology:Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4AgBiome and Genective collaborate to create novel insect-resistant crops 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3
... China, April 24 /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, ... (OTC Bulletin,Board: CSKI), a pharmaceutical company for external ... ("PRC"), today announced it,acquired Heilongjiang Haina Pharmaceutical Inc. ... laws of the PRC on April,18, 2008., ...
... announced today that Chairman and CEO Fred Hassan purchased,just ... 000 shares at,an average purchase price of $18.26 per ... intention to purchase these shares in,January, this investment in ... -- including ZETIA and VYTORIN --,and our late- stage ...
... 24 /PRNewswire/ - Aegera Therapeutics Inc. is very,pleased ... and,financial executives to its Board of Directors: Mr. ... Managers Limited, and Mr. Gary,Littlejohn, Managing Director of ... experience and networks will be,critical for Aegera as ...
Cached Biology Technology:China Sky One Medical, Inc. Acquires Heilongjiang Haina Pharmaceutical Inc. 2China Sky One Medical, Inc. Acquires Heilongjiang Haina Pharmaceutical Inc. 3Aegera Therapeutics welcomes two experienced executives to its board of directors 2
(Date:6/30/2015)... 30, 2015 To bolster its efforts and commitment ... announced today the addition of two new team members. ... advisor and David Raviv will act as head ... Corp.,s commitment to providing the most secure solutions for the ... co-founded Layer 7 Technologies, a provider of security and management ...
(Date:6/30/2015)... 30, 2015 Genisphere announced ... to help further develop Genisphere,s therapeutics capabilities and portfolio. ... having spent much of the last 25 years in ... Bioscience, and Johnson & Johnson. Tom started his career ... Biotech Corporate Finance. He graduated from Dartmouth College with ...
(Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ) has ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Biomedical Sensors market is estimated at $0.65 billion by ... 2014-2020 The near future will bring Biomedical ... each individual. These sensors can be set to trigger ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Latin America Biomedical Sensors Market Report 2015-2020 2
... serve society in numerous waysby providing timber, habitat ... example. Management of these multiple resources is a ... May 2007, the agency co-sponsored a biennial workshop ... researchers designed to present and discuss new ideas ...
... as stocks have declined sharply across the North Atlantic. ... mysterious as its long migrations, a recent study by ... United Kingdom says shifts in ocean-atmosphere conditions may be ... Although many aspects of spawning and early ...
... that helped Houston avoid the title of Americas smoggiest city ... to an $8.8 million grant from the Texas Commission on ... and Research Center at the University of Houston intends to ... and a heavy-duty engine dynamometer, a machine that tests an ...
Cached Biology News:Changes in ocean conditions in Sargasso Sea potential cause for decline in eel fishery 2Changes in ocean conditions in Sargasso Sea potential cause for decline in eel fishery 3State, UH teaming up to reduce (ob)noxious air emissions 2
... The Beacon 2000 Fluorescence Polarization System ... research and assay development. Standard Beacon ... 2000 System uses a quartz-halogen lamp ... of 360-700 nm. It accommodates all ...
The bench-top stand comfortably holds up to 6 Finnpipette Digital single- and multichannel pipettes. The crossbars are made of a grippy material to keep the pipettes firmly in place. Individual shelf...
Preparation Note: Prepared essentially by method of Singer, T.P., J. Biol. Chem., 174, 11 (1948). Quality Clarifier: Contains lipase Unit Definition: One unit will hydrolyze 1.0 μmole of p-ni...
... (PPase-2A) is a serine/threonine phosphatase isolated from ... as the heterodimer of 60kDa (A) and ... to dephosphorylate the a-subunit of phosphorylase kinase. ... broad substrate specificity and may play a ...
Biology Products: